Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

Abstract Background Cabozantinib was approved by the European Medicines Agency and the Federal Drug Administration as an option for sorafenib-resistant advanced hepatocellular carcinoma, increasing overall survival and progression-free survival compared with placebo. We evaluated the cost-effectiven...

Descripció completa

Dades bibliogràfiques

Autors principals:	Maximilian Sieg, Michael Hartmann, Utz Settmacher, Habibollah Arefian
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2020-04-01
Col·lecció:	BMC Gastroenterology
Matèries:	Hepatocellular carcinoma Cost-effectiveness Cabozantinib Second-line therapy
Accés en línia:	http://link.springer.com/article/10.1186/s12876-020-01241-y
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!